General Toxicity Notes
Headache, edema, flushing, dizziness.
Half-Life (Normalesrd) Hours
2/5-7
Plasma Protein Binding %
97
Volume Of Distribution L/Kg
1.4
Dose For Normal Renal Function
10-30 mg q8h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No dose adjustment, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: No dose adjustment,[A]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50,titrate, [D]
References
Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet. 1996; 30: 28-51. [PMID: 8846626] / Kleinbloesem CH, van Brummelen P, Woittiez AJ, Faber H, Breimer DD. Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion. Clin Pharmacokinet. 1986; 11: 316-22. [PMID: 3757391] / Sorkin EM, Clissold SP, Brogden RN. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs. 1985; 30: 182-274. [PMID: 2412780]
Toxicity Notes
Acute renal dysfunction. Protein binding decreased in ESRD. May increase digoxin levels. Data are for nifedipine immediate release. Sustained-release doses are 30-90 mg once daily.